Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues
The patients with progressive metastatic radioiodine refractory differentiated thyroid cancer have a rather unfavorable prognosis. Their life expectancy, according to various authors, does not exceed 3–5 years. To date, tyrosine kinase inhibitors have demonstrated their effectiveness in the treatmen...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-03-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/1041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240841833414656 |
|---|---|
| author | E. V. Borodavina A. Yu. Shurinov V. V. Krylov |
| author_facet | E. V. Borodavina A. Yu. Shurinov V. V. Krylov |
| author_sort | E. V. Borodavina |
| collection | DOAJ |
| description | The patients with progressive metastatic radioiodine refractory differentiated thyroid cancer have a rather unfavorable prognosis. Their life expectancy, according to various authors, does not exceed 3–5 years. To date, tyrosine kinase inhibitors have demonstrated their effectiveness in the treatment of such patients, and in particular, lenvatinib, which is recommended by all leading world communities as the first line of targeted therapy for such patients. The undoubted benefit of targeted therapy with lenvatinib is associated with the development of a fairly large number of adverse events and, accordingly, a decrease in the quality of life of patients. To date, most experts have come to the unambiguous conclusion that there is no need to rush to prescribe targeted therapy without real need. Unfortunately, despite the huge number of different schools and conferences devoted to this topic, most specialists have quite limited experience in the treatment and dynamic observation of patients with progressive radioiodine refractory differentiated thyroid cancer.In this article, using a clinical example, we will try to shed light on the difficulties encountered in the treatment of patients with progressive metastatic radiodefractive differentiated thyroid cancer. |
| format | Article |
| id | doaj-art-eb003ca71f954b1ab9b505c19f931902 |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2025-03-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-eb003ca71f954b1ab9b505c19f9319022025-08-20T04:00:26ZrusABV-pressОпухоли головы и шеи2222-14682411-46342025-03-01151404610.17650/2222-1468-2025-15-1-40-46624Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issuesE. V. Borodavina0A. Yu. Shurinov1V. V. Krylov2A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of RussiaA.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of RussiaA.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of RussiaThe patients with progressive metastatic radioiodine refractory differentiated thyroid cancer have a rather unfavorable prognosis. Their life expectancy, according to various authors, does not exceed 3–5 years. To date, tyrosine kinase inhibitors have demonstrated their effectiveness in the treatment of such patients, and in particular, lenvatinib, which is recommended by all leading world communities as the first line of targeted therapy for such patients. The undoubted benefit of targeted therapy with lenvatinib is associated with the development of a fairly large number of adverse events and, accordingly, a decrease in the quality of life of patients. To date, most experts have come to the unambiguous conclusion that there is no need to rush to prescribe targeted therapy without real need. Unfortunately, despite the huge number of different schools and conferences devoted to this topic, most specialists have quite limited experience in the treatment and dynamic observation of patients with progressive radioiodine refractory differentiated thyroid cancer.In this article, using a clinical example, we will try to shed light on the difficulties encountered in the treatment of patients with progressive metastatic radiodefractive differentiated thyroid cancer.https://ogsh.abvpress.ru/jour/article/view/1041progressive metastatic radioiodine refractory differentiated thyroid cancerprogressionthyroglobulinresponse evaluation criteria in solid tumorstargeted therapylenvatinibresponse to treatment |
| spellingShingle | E. V. Borodavina A. Yu. Shurinov V. V. Krylov Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues Опухоли головы и шеи progressive metastatic radioiodine refractory differentiated thyroid cancer progression thyroglobulin response evaluation criteria in solid tumors targeted therapy lenvatinib response to treatment |
| title | Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues |
| title_full | Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues |
| title_fullStr | Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues |
| title_full_unstemmed | Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues |
| title_short | Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues |
| title_sort | advanced metastatic radioiodine refractory differentiated thyroid cancer current treatment and dynamic surveillance issues |
| topic | progressive metastatic radioiodine refractory differentiated thyroid cancer progression thyroglobulin response evaluation criteria in solid tumors targeted therapy lenvatinib response to treatment |
| url | https://ogsh.abvpress.ru/jour/article/view/1041 |
| work_keys_str_mv | AT evborodavina advancedmetastaticradioiodinerefractorydifferentiatedthyroidcancercurrenttreatmentanddynamicsurveillanceissues AT ayushurinov advancedmetastaticradioiodinerefractorydifferentiatedthyroidcancercurrenttreatmentanddynamicsurveillanceissues AT vvkrylov advancedmetastaticradioiodinerefractorydifferentiatedthyroidcancercurrenttreatmentanddynamicsurveillanceissues |